Lifecore Biomedical, Inc. LFCR
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | -596.83% | -596.83% |
| Total Depreciation and Amortization | -- | -- | -- | 3.03% | 3.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | 366.25% | 366.25% |
| Change in Net Operating Assets | -- | -- | -- | -244.61% | -244.61% |
| Cash from Operations | -- | -- | -- | -72.32% | -72.32% |
| Capital Expenditure | -- | -- | -- | 29.72% | 29.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 71.55% | 71.55% |
| Total Debt Issued | -- | -- | -- | -7.01% | -7.01% |
| Total Debt Repaid | -- | -- | -- | -7.45% | -7.45% |
| Issuance of Common Stock | -- | -- | -- | 2,385,600.00% | 2,385,600.00% |
| Repurchase of Common Stock | -- | -- | -- | -29.93% | -29.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -78.34% | -78.34% |
| Cash from Financing | -- | -- | -- | -30.43% | -30.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | 144.27% | 144.27% |